Larimar Therapeutics
completed phase multiple ascending dose study | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
9 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
completed phase multiple ascending dose study | Larimar Therapeutics
Related slides by other companies
Arbutus Biopharma
Results
November 2022
demonstrates target engagement in cells in a mouse model | Arbutus Biopharma
DICE Therapeutics
Results
March 2023
reductions in systemic by suggest potential for significant long term pasi responses bid | DICE Therapeutics
ATAI
Investor Presentation
October 2022
part sad study completed august healthy adult participants cohort cohort cohort cohort cohort fed cohort in addition to safety including respiratory and assessments evoked pain tests were administered to all cohorts part comparator study results by healthy male participants single oral dose single oral dose single oral dose single oral dose single oral dose single oral dose matching placebo matching placebo matching placebo day single dose day washout day single dose day washout day single dose this phase is designed unlock the therapeutic potential improved profile of | ATAI
Kymera
Investor Day
December 2021
mad reduced to near in the skin | Kymera
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights